ReviewExperimental hematology & oncology2021

Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment.

Mohsen Valikhani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.